Initiation of legal actions against Covid-19 vaccine manufacturer due to adverse effects.
-
Dr. Philip McMillan’s research focuses on autoimmunity related to viral infections or vaccines. • 0:05
-
AstraZeneca facing two lawsuits in London over Covid-19 vaccines. • 1:06
-
One lawsuit filed by a man whose wife died after receiving the vaccine. • 2:24
-
The husband filed a product liability claim against AstraZeneca. • 2:34
-
There is uncertainty regarding suing the government due to indemnity. • 2:52
-
The woman who passed away was only 35 years old. • 3:12
Initiation of legal actions related to Covid-19 vaccines due to lack of information on risks and adverse events.
-
Healthy mother died in March 2021 after receiving AstraZeneca vaccine in September 2021. • 3:23
-
Concern over insufficient information about vaccine risks leading to product liability challenges. • 3:40
-
AstraZeneca vaccine highlighted due to higher reporting rate of adverse events per 100,000 doses compared to Pfizer. • 5:07
-
Many countries discontinued AstraZeneca vaccine use in favor of Pfizer or Moderna vaccines. • 6:03
Risks associated with AstraZeneca COVID-19 vaccine leading to potential lawsuits and industry impact.
-
AstraZeneca shows four times higher risk compared to Pfizer and Moderna vaccine. • 6:42
-
Lack of long-term research raises concerns over safety and effectiveness claim. • 7:31
-
Thrombosis with thrombocytopenia syndrome linked to serious cases reporte. • 8:09
-
21 reports of vaccine-induced immune thrombotic thrombocytopenia in Ontario out of a million case. • 8:26
-
Anticipation of lawsuits expanding beyond AstraZeneca to impact entire vaccine industr. • 9:07
-
Visible complications with AstraZeneca possibly due to changes in spike protei. • 9:16
Analysis of vaccine spike proteins' impact on autoimmune response and antibody generation.
-
AstraZeneca and Moderna made adjustments to spike proteins to reduce autoimmune response. • 9:40
-
IGG 4 response was more common with mRNA vaccines compared to adenovirus-based vaccines. • 11:22
-
Circulating spike protein fragments may be more prevalent with mRNA vaccines due to immune system challenges. • 12:16
Implications of vaccine lawsuits due to potential long-term effects and financial burden.
-
Risks of significant morbidity or mortality due to vaccine impact with virus circulation. • 13:05
-
Speculation on autoimmunity risks from vaccine-variant combination. • 13:39
-
Concerns over lawsuits leading to financial burden on taxpayers. • 14:15
-
Importance of finding objective answers to protect and support those affected. • 14:45